Clinical trial
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or…
NCT00193050 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193050 |
|---|---|
| Title | Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer |
| Official title | Phase II Trial of Induction Chemotherapy With Weekly Gemcitabine, Epirubicin, Docetaxel as Primary Treatment of Locally Advanced or Inflammatory Breast Cancer Patients |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Pharmacia and Upjohn Industry Eli Lilly and Company Aventis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Epirubicin, Docetaxel |
| Enrollment | 110 |
| Start date | Nov 1, 2001 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 26, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: